Navigation Links
The Chinese Electrophysiology Device Market Will See an Annual Procedure Growth of 20 Percent
Date:9/12/2013

TORONTO, Sept. 12, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, electrophysiology catheter ablation is a rapidly growing procedure in China. MRG predicts that the Chinese electrophysiology market will grow approximately 20 percent in 2013, based on the largest available sampling of ablation procedures.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

Following coronary angioplasty, electrophysiology catheter ablation is the second most commonly performed cardiovascular intervention in China. According to the Ministry of Health registry for cardiovascular interventions, 74,400 catheter ablations occurred in mainland China in 2012, but this number excludes procedures at military hospitals. Taking these additional procedures into account, MRG estimates that more than 100,000 EP catheter ablation procedures will be performed in China in 2013.

In contrast to the Chinese market for coronary stents used in coronary angioplasty, where local players dominate, the electrophysiology catheter market is led by multinational manufacturers. Local Chinese companies have approximately 10 percent of the market, with Microport having the largest share. Among multinational companies, JNJ Biosense Webster is leading the market, with St. Jude second, and Medtronic third. Boston Scientific announced the acquisition of Bard's electrophysiology business in June 2013, which will give the company a significant market share and put it on a more equal footing with leading competitors.

"The electrophysiology market in China is the second largest cardiac market in terms of numbers of procedures," said MRG Project Analyst Thomas Lee. "Its competitive picture is complex. Six multinationals have positions in this market, along with the local players. We expect that Microport will continue to grow their position in this market, especially when the company introduces their first line of pacemakers into China.  We are tracking these procedures in 100 hospitals across 25 provinces. The data we are acquiring will allow us to estimate growth in electrophysiology procedures throughout the calendar year, as well as track device use by brand."

Despite the speed of this market's growth, only 24 percent of these procedures were for atrial fibrillation, the most common cardiac arrhythmia. This proportion is far less than that in the more mature US and European markets. This undertreated population presents a significant market opportunity for device manufacturers, particularly since atrial fibrillation procedures use premium-priced high-end catheters.

These results can be found in a new tracking study from MRG: China Electrophysiology Marketrack. This study fields quarterly to 100 hospitals across 25 provinces and tracks procedure growth, device market size, price per device and brand usage on a quarterly basis.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: 

Christopher Comfort
Decision Resources, Inc.
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net

 


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
2. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
3. PharmaNet/i3 Receives Distinguished Partner Award from the US Chinese Anti-Cancer Association
4. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
5. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
6. Chinese Market for Medical Imaging Equipment to Exceed $2.5 billion by 2016
7. MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market
8. Brazilian, Indian and Chinese Orthopedic Markets to See Strong Growth Through 2017
9. NeuroAiD(TM), a Stroke Treatment Based on Traditional Chinese Medicine, More than Doubles the Chances of Achieving Independence after Stroke
10. Doing Business in China: Research on Chinese Good Manufacturing Practice Regulations for Medical Devices
11. 2013 Chinese Pharmaceutical Guidebook: Drug Registration Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):